KALA BIO (KALA)

Last close As at 27/10/2025

USD0.81

0.01 (1.26%)

Market capitalisation

USD6m

KALA BIO is a clinical-stage biotechnology company advancing its proprietary mesenchymal stem cell secretome (MSC-S) platform towards rare eye diseases, with lead candidate KPI-012 targeting ocular surface diseases.

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Todd Bazemore

    CEO

  • Mary Reumuth

    CFO

Thematics